Details of the Drug Combination

General Information of Drug Combination (ID: DC7FRNK)

Drug Combination Name
Meropenem Levofloxacin
Indication
Disease Entry Status REF
Complicated Urinary Tract Infection Phase 3 [1]
Component Drugs Meropenem   DM62UHC Levofloxacin   DMS60RB
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Meropenem
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [2]
Meningococcal meningitis N.A. Approved [3]
Peritonitis N.A. Approved [3]
Pneumococcal meningitis N.A. Approved [3]
Pseudomonas aeruginosa infectious disease N.A. Approved [3]
Meropenem Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Penicillin binding protein (Bact PBP) TTJP4SM NOUNIPROTAC Modulator [6]
------------------------------------------------------------------------------------
Meropenem Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic anion transporter 1 (SLC22A6) DTQ23VB S22A6_HUMAN Substrate [7]
------------------------------------------------------------------------------------
Meropenem Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Beta-lactamase (blaB) DEC3G7M A0A1S7IV31_ENTAS Metabolism [8]
Beta-lactamase (blaB) DENJ2SQ BLAB_BACFG Metabolism [9]
Beta-lactamase (blaB) DEBKS91 A0A1B1FBM9_ACIBA Metabolism [10]
Beta-lactamase (blaB) DECWSA9 AMPC_MORMO Metabolism [11]
Carbapenemase (cphA) DEB90AL BLAB_AERHY Metabolism [12]
New delhi metallo-beta-lactamase NDM-1 (blaNDM) DEBGCYQ A0A345N7K5_SALET Metabolism [13]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Meropenem Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
HLA class II histocompatibility antigen, DO beta chain (HLA-DOB) OTKADDUB DOB_HUMAN Affects Expression [14]
HLA class I histocompatibility antigen, alpha chain G (HLA-G) OTMLK1KN HLAG_HUMAN Affects Expression [14]
------------------------------------------------------------------------------------
Indication(s) of Levofloxacin
Disease Entry ICD 11 Status REF
Acute maxillary sinusitis N.A. Approved [4]
Anthrax 1B97 Approved [4]
Bacterial infection 1A00-1C4Z Approved [5]
Latent tuberculosis infection N.A. Approved [4]
Mycoplasma pneumoniae pneumonia N.A. Approved [4]
Pyelonephritis N.A. Approved [4]
Staphylococcal pneumonia N.A. Approved [4]
Staphylococcus aureus infection N.A. Approved [4]
Streptococcal pneumonia N.A. Approved [4]
Pneumonia caused by chlamydia N.A. Investigative [4]
Levofloxacin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [6]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [6]
------------------------------------------------------------------------------------
Levofloxacin Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [15]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [16]
------------------------------------------------------------------------------------
Levofloxacin Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Beta-lactamase (blaB) DEP0IWS A0A378EHS6_KLEPR Metabolism [17]
------------------------------------------------------------------------------------
Levofloxacin Interacts with 11 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Dihydrofolate reductase (DHFR) OT3DVIGM DYR_HUMAN Decreases Activity [18]
Interleukin-1 alpha (IL1A) OTPSGILV IL1A_HUMAN Increases Expression [19]
Antileukoproteinase (SLPI) OTUNFUU8 SLPI_HUMAN Decreases Expression [19]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [19]
Bone morphogenetic protein 6 (BMP6) OT9WN536 BMP6_HUMAN Decreases Expression [19]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Decreases Expression [19]
Tumor necrosis factor-inducible gene 6 protein (TNFAIP6) OT1SLUZH TSG6_HUMAN Decreases Expression [19]
Interleukin-24 (IL24) OT4VUWH1 IL24_HUMAN Increases Expression [19]
PTB-containing, cubilin and LRP1-interacting protein (PID1) OT5YJ7FI PCLI1_HUMAN Decreases Expression [19]
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B) OTUYHB84 MLP3B_HUMAN Increases Expression [20]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Increases Expression [19]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DOT(s)

References

1 ClinicalTrials.gov (NCT02486627) A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 Meropenem FDA Label
4 Levofloxacin FDA Label
5 How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Characterization of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters. Drug Metab Pharmacokinet. 2007 Feb 25;22(1):41-7.
8 FRI-4 carbapenemase-producing Enterobacter cloacae complex isolated in Tokyo, Japan. J Antimicrob Chemother. 2018 Nov 1;73(11):2969-2972.
9 Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
10 A high mortality rate associated with multidrug-resistant Acinetobacter baumannii ST79 and ST25 carrying OXA-23 in a Brazilian intensive care unit. PLoS One. 2018 Dec 28;13(12):e0209367.
11 Molecular investigation of extended-spectrum beta-lactamase genes and potential drug resistance in clinical isolates of Morganella morganii. Ann Saudi Med. 2016 May-Jun;36(3):223-8.
12 A carbapenem-resistant clinical isolate of Aeromonas hydrophila in Japan harbouring an acquired gene encoding GES-24 beta-lactamase. J Med Microbiol. 2018 Nov;67(11):1535-1537.
13 Genomic characterization of an extensively-drug resistance Salmonella enterica serotype Indiana strain harboring bla NDM-1 gene isolated from a chicken carcass in China. Microbiol Res. 2017 Nov;204:48-54.
14 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
15 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
16 Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
17 Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8.
18 Investigation of the effects of some drugs and phenolic compounds on human dihydrofolate reductase activity. J Biochem Mol Toxicol. 2015 Mar;29(3):135-9.
19 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
20 TNF enhances trovafloxacin-induced in vitro hepatotoxicity by inhibiting protective autophagy. Toxicol Lett. 2021 May 15;342:73-84. doi: 10.1016/j.toxlet.2021.02.009. Epub 2021 Feb 17.